Abstract:Laser photocoagulation (LPC) and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections constitute the current standard treatment for retinopathy of prematurity (ROP). This network meta-analysis focus on whether a ranking of interventions may be established for different dose levels of intravitreal injection of anti-VEGF agents (aflibercept, bevacizumab, conbercept, ranibizumab) as primary treatments for ROP versus laser in terms of retreatment rate as primary outcome, and time to retreatment and refractive error as secondary endpoints, since best anti-VEGF dosage remains under debate. Sixty-eight studies (15 randomized control trials and 53 nonrandomized studies) of 12,356 eyes of 6,445 infants were retrieved from databases (2005 Jan. – 2023 June). Studies were evaluated for model fit, risk of bias and confidence of evidence in Network Meta-Analysis (CINeMA). Bayesian NMA showed that anti-VEGF drugs were not inferior to laser in terms of retreatment rate. For intravitreal bevacizumab (IVB), doses half of the conventional infant dose showed a low risk of retreatment rate (risk ratio (RR) of 1.43; 95% credible interval (CrI): 0.508, 4.03). On probability ranking as surface under the cumulative ranking curve (SUCRA) plot, half dose of bevacizumab had a better position than conventional and augmented (1.2-2 times the regular dose) doses. A similar probability trend was observed for half vs. conventional doses of aflibercept and ranibizumab. Conventional infant dose of conbercept showed the lowest risk for retreatment (RR 0.846; 95% CrI: 0.245, 2.91). For secondary endpoints, lower doses of anti-VEGF agents were associated with shorter times to retreatment. The largest changes were noted for the augmented doses of bevacizumab and ranibizumab (0.3 mg) with means of 14.1 weeks (95% CrI: 6.65, 21.6) and 12.8 weeks (95% CrI: 3.19, 20.9), respectively. Finally, NMA demonstrated better refractive profile for anti-VEGF than laser therapy, especially for the conventional infant doses of bevacizumab and ranibizumab which exhibited a significantly better refractive profile than LPC, with mean differences of 1.67 (spherical equivalent - diopters) (95% CrI: 0.705, 2.67) and 2.19 (95% CrI: 0.782, 3.59), respectively. In the SUCRA plots, LPC had a markedly different position with a higher probability for myopia. Further clinical trials comparing different intravitreal doses of anti-VEGF agents are needed, but our findings suggest that low doses of these drugs retain efficacy and may reduce ocular and systemic undesired events.

Do intravitreal anti-VEGF injections have an effect on corneal endothelial remodeling in children with premature retinopathy?

Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser

The effect of intravitreal anti-vascular endothelial growth factor injections on corneal endothelium in patients with diabetic macular oedema

Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Nationwide Database Study

Long-term surgical outcomes and prognostic factors for advanced-stage retinopathy of prematurity after vitrectomy

Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment

Efficacy and Safety of Aflibercept and Ranibizumab in the Treatment of Retinopathy of Prematurity

Foveal Structure Changes in Infants Treated with Anti-Vegf Therapy or Laser Therapy Guided by Optical Coherence Tomography Angiography for Retinopathy of Prematurity.

Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors

Long-term outcomes of visual motor integration and motor development children with retinopathy of prematurity

Comparison of Intravitreal Anti-VEGF Agents with Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China.

The Analysis of Foveal Microvascular Anomalies in Retinopathy of Prematurity after Anti-Vascular Endothelial Growth Factor Therapy Using Optical Coherence Tomography Angiography

Serum Vascular Endothelial Growth Factor Levels Before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity

Intravitreal anti-VEGF treatment for retinopathy of prematurity in infants with active adenoviral keratoconjunctivitis

Ocular Biometric and Optical Coherence Tomography Parameters in Former Preterm Children: A Cohort Study

Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis

Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group

Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion

Systemic Conbercept Pharmacokinetics and VEGF Pharmacodynamics Following Intravitreal Injections of Conbercept in Patients with Retinopathy of Prematurity

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept Versus Ranibizumab for Retinopathy of Prematurity.

Efficacy Comparison of Anti-Vascular Endothelial Growth Factor Drugs for the Treatment of Type 1 Retinopathy of Prematurity: A Network Meta-Analysis of Randomised Controlled Trials.